Biohaven Pharmaceutical Net Worth
Biohaven Pharmaceutical Net Worth Breakdown | BHVN |
Biohaven Pharmaceutical Net Worth Analysis
Biohaven Pharmaceutical's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Biohaven Pharmaceutical's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Biohaven Pharmaceutical's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Biohaven Pharmaceutical's net worth analysis. One common approach is to calculate Biohaven Pharmaceutical's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Biohaven Pharmaceutical's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Biohaven Pharmaceutical's net worth. This approach calculates the present value of Biohaven Pharmaceutical's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Biohaven Pharmaceutical's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Biohaven Pharmaceutical's net worth. This involves comparing Biohaven Pharmaceutical's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Biohaven Pharmaceutical's net worth relative to its peers.
Enterprise Value |
|
To determine if Biohaven Pharmaceutical is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Biohaven Pharmaceutical's net worth research are outlined below:
| Biohaven Pharmaceutical generated a negative expected return over the last 90 days | |
| Biohaven Pharmaceutical has high historical volatility and very poor performance | |
| Biohaven Pharmaceutical Holding currently holds 32.78 M in liabilities with Debt to Equity (D/E) ratio of 0.22, which may suggest the company is not taking enough advantage from borrowing. Biohaven Pharmaceutical has a current ratio of 0.7, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Biohaven Pharmaceutical's use of debt, we should always consider it together with its cash and equity. | |
| Net Loss for the year was (846.42 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Biohaven Pharmaceutical Holding currently holds about 23.21 M in cash with (582.45 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.48. | |
| Over 92.0% of Biohaven Pharmaceutical shares are held by institutions such as insurance companies | |
| Latest headline from kalkinemedia.com: How Is Biohaven Ltd. Supporting Its Clinical Trials |
Biohaven Pharmaceutical Quarterly Good Will |
|
Biohaven Pharmaceutical uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Biohaven Pharmaceutical Holding. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Biohaven Pharmaceutical's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 28th of March 2024 Upcoming Quarterly Report | View | |
| 10th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 28th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Biohaven Pharmaceutical's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Biohaven Pharmaceutical is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Biohaven Pharmaceutical Holding backward and forwards among themselves. Biohaven Pharmaceutical's institutional investor refers to the entity that pools money to purchase Biohaven Pharmaceutical's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Jpmorgan Chase & Co | 2024-12-31 | 2 M | Geode Capital Management, Llc | 2024-12-31 | 1.9 M | Citadel Advisors Llc | 2024-12-31 | 1.7 M | Armistice Capital, Llc | 2024-12-31 | 1.7 M | Holocene Advisors, Lp | 2024-12-31 | 1.1 M | Schmeidler A R & Co Inc | 2024-12-31 | 1 M | Brown Advisory Holdings Inc | 2024-12-31 | 975.6 K | Point72 Asset Management, L.p. | 2024-12-31 | 923 K | Nuveen Asset Management, Llc | 2024-12-31 | 919.2 K | Vanguard Group Inc | 2024-12-31 | 8.4 M | Blackrock Inc | 2024-12-31 | 7.7 M |
Follow Biohaven Pharmaceutical's market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 3.17 B.Market Cap |
|
Project Biohaven Pharmaceutical's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.42) | (1.49) | |
| Return On Capital Employed | (1.92) | (2.02) | |
| Return On Assets | (1.38) | (1.44) | |
| Return On Equity | (2.00) | (1.90) |
When accessing Biohaven Pharmaceutical's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Biohaven Pharmaceutical's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Biohaven Pharmaceutical's profitability and make more informed investment decisions.
Evaluate Biohaven Pharmaceutical's management efficiency
Biohaven Pharmaceutical has return on total asset (ROA) of (0.9685) % which means that it has lost $0.9685 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.9883) %, meaning that it created substantial loss on money invested by shareholders. Biohaven Pharmaceutical's management efficiency ratios could be used to measure how well Biohaven Pharmaceutical manages its routine affairs as well as how well it operates its assets and liabilities. As of the 26th of March 2025, Return On Tangible Assets is likely to drop to -1.49. In addition to that, Return On Capital Employed is likely to drop to -2.02. At this time, Biohaven Pharmaceutical's Non Currrent Assets Other are very stable compared to the past year. As of the 26th of March 2025, Net Tangible Assets is likely to grow to about 626.3 M, while Total Assets are likely to drop about 388.4 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 4.64 | 3.64 | |
| Tangible Book Value Per Share | 4.42 | 3.30 | |
| Enterprise Value Over EBITDA | (3.77) | (3.96) | |
| Price Book Value Ratio | 8.05 | 8.45 | |
| Enterprise Value Multiple | (3.77) | (3.96) | |
| Price Fair Value | 8.05 | 8.45 | |
| Enterprise Value | 3.3 B | 3.5 B |
The leadership approach at Biohaven Pharmaceutical's fosters a culture of excellence and accountability. Our analysis examines how this culture influences financial outcomes and stock valuation.
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Biohaven Pharmaceutical insiders, such as employees or executives, is commonly permitted as long as it does not rely on Biohaven Pharmaceutical's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Biohaven Pharmaceutical insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Biohaven Pharmaceutical Corporate Filings
| 18th of March 2025 Other Reports | ViewVerify | |
| 5th of March 2025 Other Reports | ViewVerify | |
10K | 3rd of March 2025 Annual report required by the U.S. Securities and Exchange Commission (SEC) of a company financial performance | ViewVerify |
| 14th of February 2025 Other Reports | ViewVerify |
Biohaven Pharmaceutical Earnings per Share Projection vs Actual
Biohaven Pharmaceutical Corporate Directors
| John Childs | Independent Director | Profile | |
| Robert Hugin | Independent Director | Profile | |
| Michael Heffernan | Lead Independent Director | Profile | |
| Julia Gregory | Independent Director | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biohaven Pharmaceutical Holding. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biohaven Pharmaceutical. If investors know Biohaven will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biohaven Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Biohaven Pharmaceutical is measured differently than its book value, which is the value of Biohaven that is recorded on the company's balance sheet. Investors also form their own opinion of Biohaven Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Biohaven Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biohaven Pharmaceutical's market value can be influenced by many factors that don't directly affect Biohaven Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biohaven Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biohaven Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biohaven Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.